Ignasi Bofill Verdaguer

Ignasi Bofill Verdaguer

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2022 in Molecules
Verified
Journal Article
Open access
PDF file
IVIgnasi Bofill Verdaguer
Ignasi Bofill Verdaguer
MCMarcell Crispim
Marcell Crispim
Agustin HernándezAgustin Hernández
Agustin Hernández
AKAlejandro Katzin
Alejandro Katzin
Isoprenoids are the output of the polymerization of five-carbon, branched isoprenic chains derived from isopentenyl pyrophosphate (IPP) and its isomer, dimethylallyl pyrophosphate (DMAPP). Isoprene units are consecutively condensed to form longer structures such as farnesyl and geranylgeranyl pyrophosphate (FPP and GGPP, respectively), necessary for the biosynthesis of several metabolites. Polyprenyl transferases and synthases use polyprenyl pyrophosphates as their natural substrates; however, it is known that free polyprenols, such as farnesol (FOH), and geranylgeraniol (GGOH) can be incorporated into prenylated proteins, ubiquinone, cholesterol, and dolichols. Furthermore, FOH and GGOH have been shown to block the effects of isoprenoid biosynthesis inhibitors such as fosmidomycin, bisphosphonates, or statins in several organisms. This phenomenon is the consequence of a short pathway, which was observed for the first time more than 25 years ago: the polyprenol salvage pathway, which works via the phosphorylation of FOH and GGOH. Biochemical studies in bacteria, animals, and plants suggest that this pathway can be carried out by two enzymes: a polyprenol kinase and a polyprenyl-phosphate kinase. However, to date, only a few genes have been unequivocally identified to encode these enzymes in photosynthetic organisms. Nevertheless, pieces of evidence for the importance of this pathway abound in studies related to infectious diseases, cancer, dyslipidemias, and nutrition, and to the mitigation of the secondary effects of several drugs. Furthermore, nowadays it is known that both FOH and GGOH can be incorporated via dietary sources that produce various biological effects. This review presents, in a simplified but comprehensive manner, the most important data on the FOH and GGOH salvage pathway, stressing its biomedical importance The main objective of this review is to bring to light the need to discover and characterize the kinases associated with the isoprenoid salvage pathway in animals and pathogens.

16 October 2019 in Molecules
Verified
Journal Article
Open access
PDF file
IVIgnasi Bofill Verdaguer
Ignasi Bofill Verdaguer
CZCamila Zafra
Camila Zafra
MCMarcell Crispim
Marcell Crispim
RSRodrigo Sussmann
Rodrigo Sussmann
EKEmília A. Kimura
Emília A. Kimura
AKAlejandro Katzin
Alejandro Katzin
Human parasitic protozoa cause a large number of diseases worldwide and, for some of these diseases, there are no effective treatments to date, and drug resistance has been observed. For these reasons, the discovery of new etiological treatments is necessary. In this sense, parasitic metabolic pathways that are absent in vertebrate hosts would be interesting research candidates for the identification of new drug targets. Most likely due to the protozoa variability, uncertain phylogenetic origin, endosymbiotic events, and evolutionary pressure for adaptation to adverse environments, a surprising variety of prenylquinones can be found within these organisms. These compounds are involved in essential metabolic reactions in organisms, for example, prevention of lipoperoxidation, participation in the mitochondrial respiratory chain or as enzymatic cofactors. This review will describe several prenylquinones that have been previously characterized in human pathogenic protozoa. Among all existing prenylquinones, this review is focused on ubiquinone, menaquinone, tocopherols, chlorobiumquinone, and thermoplasmaquinone. This review will also discuss the biosynthesis of prenylquinones, starting from the isoprenic side chains to the aromatic head group precursors. The isoprenic side chain biosynthesis maybe come from mevalonate or non-mevalonate pathways as well as leucine dependent pathways for isoprenoid biosynthesis. Finally, the isoprenic chains elongation and prenylquinone aromatic precursors origins from amino acid degradation or the shikimate pathway is reviewed. The phylogenetic distribution and what is known about the biological functions of these compounds among species will be described, as will the therapeutic strategies associated with prenylquinone metabolism in protozoan parasites.

19 December 2018
Verified
Book Chapter
Open access
PDF file
HGHeloisa Berti Gabriel
Heloisa Berti Gabriel
RSRodrigo Sussmann
Rodrigo Sussmann
EKEmila A Kimura
Emila A Kimura
ARAdriana Alejandra Marin Rodriguez
Adriana Alejandra Marin Rodriguez
IVIgnasi Bofill Verdaguer
Ignasi Bofill Verdaguer
AKAlejandro Katzin
Alejandro Katzin
A fact which favors the increase in morbidity and mortality of malaria cases in the world is the resistance to chemotherapeutic agents that the parasite presents. Therefore, it is necessary to identify new potential targets specific to the parasite in order to be able to perform a rational planning. One target for the evaluation of potential antimalarial compounds is isoprenoid synthesis, which occurs via the 2-C-methyl-d -erythritol-4-phosphate pathway in Plasmodium falciparum. Several intermediaries and final products of this pathway were identified in the parasite and lead us to the conclusion that it is different from the vertebrate host. In this chapter, we describe the effect of some monoterpenes and sesquiterpenes on Plasmodium falciparum and Plasmodium berghei as potential antimalarial drugs.

24 July 2024 in Applied and Environmental Microbiology
Verified
Journal Article
Closed access
AVAdam Voshall
Adam Voshall
DGDaniel J. Gutzmann
Daniel J. Gutzmann
IVIgnasi Bofill Verdaguer
Ignasi Bofill Verdaguer
MCMarcell Crispim
Marcell Crispim
CBCory H.T. Boone
Cory H.T. Boone
Kenneth NickersonKenneth Nickerson
Kenneth Nickerson
Farnesol salvage, a two-step pathway converting farnesol to farnesyl pyrophosphate (FPP), occurs in bacteria, plants, and animals. This paper investigates the presence of this pathway in fungi. Through bioinformatics, biochemistry, and physiological analyses, we demonstrate its absence in the yeasts Saccharomyces cerevisiae and Candida albicans , suggesting a likely absence across fungi. We screened 1,053 fungal genomes, including 34 from C. albicans , for potential homologs to four genes ( Arabidopsis thaliana AtFOLK , AtVTE5 , AtVTE6 , and Plasmodium falciparum PfPOLK ) known to accomplish farnesol/prenol salvage in other organisms. Additionally, we showed that 3 H-farnesol was not converted to FPP or any other phosphorylated prenol, and exogenous farnesol was not metabolized within 90 minutes at any phase of growth and did not rescue cells from the toxic effects of atorvastatin, but it did elevate the levels of intracellular farnesol (F i ). All these experiments were conducted with C. albicans . In sum, we found no evidence for farnesol salvage in fungi. IMPORTANCE: The absence of farnesol salvage constitutes a major difference in the metabolic capabilities of fungi. In terms of fungal physiology, the lack of farnesol salvage pathways relates to how farnesol acts as a quorum-sensing molecule in Candida albicans and why farnesol should be investigated for use in combination with other known antifungal antibiotics. Its absence is essential for a model (K. W. Nickerson et al., Microbiol Mol Biol Rev 88:e00081-22, 2024), wherein protein farnesylation, protein chaperones, and the unfolded protein response are combined under the unifying umbrella of a cell’s intracellular farnesol (F i ). In terms of human health, farnesol should have at least two different modes of action depending on whether those cells have farnesol salvage. Because animals have farnesol salvage, we can now see the importance of dietary prenols as well as the potential importance of farnesol in treating neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis.

26 February 2026 in Journal of Lipid Research
Verified
Journal Article
Open access
IVIgnasi Bofill Verdaguer
Ignasi Bofill Verdaguer
Agustin HernándezAgustin Hernández
Agustin Hernández
SNSandra Torres Núñez
Sandra Torres Núñez
MRMaria Rodríguez-Peiris
Maria Rodríguez-Peiris
FAFabian Arenas
Fabian Arenas
Jose Fernandez-ChecaJose Fernandez-Checa
Jose Fernandez-Checa
Acyclic terpene derivatives are well known as components of plant essential oils and insect hormones, yet their active biosynthesis also occurs in mammals. The terpenic alcohols-or prenols-geranylgeraniol (GGOH) and farnesol (FOH), together with their prenoic acids and derivatives, were identified in mammalian cells over sixty years ago but remain largely overlooked. These metabolites display diverse biological functions: they induce autophagy, inhibit tumor growth and inflammation, suppress cholesterol synthesis, enhance insulin sensitivity and cognition, regulate sexual characteristics, and promote healthy aging. In mammals, prenols arise from an age-dependent, bidirectional pathway that interconverts polyprenyl diphosphates, prenols, and prenoic acids. They can be oxidized into aldehydes and carboxylic acids or reconverted into diphosphate forms for use in protein prenylation and in the biosynthesis of ubiquinone, cholesterol, and dolichol. While enzymes catalyzing polyprenyl diphosphate dephosphorylation and oxidation steps have been partly characterized, the kinases mediating their reverse phosphorylation remain unidentified. This review summarizes current advances in the understanding of prenol metabolism in mammals, emphasizing its role in metabolic regulation, disease prevention, and longevity. By integrating biochemical and physiological evidence, we highlight the emerging view that these small terpenes constitute a fundamental yet underexplored layer of metabolic control. Greater attention to this pathway may reveal novel strategies for maintaining metabolic health and mitigating age-related disorders.

1 December 2018 in Neotropical Primates
Verified
Journal Article
Open access
PDF file
IVIgnasi Bofill Verdaguer
Ignasi Bofill Verdaguer
SSSilvio Luís Pereira De Souza
Silvio Luís Pereira De Souza
FPFernanda Dias De Paula
Fernanda Dias De Paula
SGSolange Maria Gennari
Solange Maria Gennari
JCJoaquin Quilez Cinca
Joaquin Quilez Cinca